How can I determine if a female patient is detoxified (i.e., has completed acute withdrawal, is clinically stable with normal vital signs, a CIWA‑Ar score ≤8 for at least 24 hours, has been abstinent for 3–5 days, and opioid‑free for ≥7 days) before starting naltrexone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Determine if a Female Patient is Detoxified Before Starting Naltrexone

A patient is considered adequately detoxified and ready for naltrexone when she has been completely opioid-free for a minimum of 7-10 days (for short-acting opioids) or up to 2 weeks (for buprenorphine or methadone), shows no clinical signs of withdrawal, and ideally passes a naloxone challenge test. 1

Critical Timeline Requirements

The FDA label for naltrexone is explicit about opioid-free intervals 1:

  • Short-acting opioids (heroin, oxycodone, morphine): Minimum 7-10 days opioid-free
  • Buprenorphine or methadone: Up to 2 weeks opioid-free due to risk of severe precipitated withdrawal
  • All opioids including tramadol must be discontinued

Common pitfall: Patients transitioning from buprenorphine or methadone are vulnerable to precipitated withdrawal for as long as 2 weeks, even if they appear clinically stable. This is a critical window where premature naltrexone initiation can cause severe harm 1.

Clinical Assessment Steps

1. Verify Abstinence Duration

  • Document the exact date and time of last opioid use
  • Confirm the specific opioid used (short vs. long-acting)
  • Consider urine drug screening, though there is no completely reliable method for determining adequate opioid-free period 1

2. Assess for Withdrawal Signs

The patient should show no clinical signs or symptoms of opioid withdrawal 1. Look for absence of:

  • Sweating, piloerection, mydriasis (dilated pupils)
  • Lacrimation, rhinorrhea
  • Nausea, vomiting, diarrhea, abdominal cramping
  • Tachycardia, hypertension, fever, tachypnea
  • Restlessness, irritability, anxiety
  • Myalgias, increased pain sensitivity
  • Yawning 2, 3

3. Naloxone Challenge Test (Gold Standard)

The naloxone challenge test is the most objective method when there is any question of occult opioid dependence 1. However, it should not be performed if:

  • Patient shows clinical signs/symptoms of withdrawal
  • Urine contains opioids

Intravenous Protocol:

  1. Inject 0.2 mg naloxone IV
  2. Observe for 30 seconds for withdrawal signs
  3. If no withdrawal: inject 0.6 mg naloxone
  4. Observe for additional 20 minutes

Subcutaneous Protocol:

  1. Administer 0.8 mg naloxone SC
  2. Observe for 20 minutes

Interpretation:

  • Positive test (withdrawal signs appear): Do NOT start naltrexone; repeat challenge in 24 hours
  • Negative test (no withdrawal): May initiate naltrexone if no other contraindications
  • Any doubt: Hold naltrexone and repeat in 24 hours 1

For Alcohol Withdrawal Context

If the question pertains to alcohol detoxification before naltrexone for alcohol use disorder:

The patient is detoxified when the CIWA-Ar score is ≤8 for at least 24 hours, vital signs are stable, and acute withdrawal symptoms have resolved 4. The CIWA-Ar scale is the gold standard for alcohol withdrawal assessment 4:

  • CIWA-Ar ≤8: Mild or no withdrawal; monitoring only
  • CIWA-Ar >8: Moderate withdrawal requiring treatment
  • CIWA-Ar ≥15: Severe withdrawal

Alcohol withdrawal typically develops within 6-24 hours after last drink, peaks at 48-72 hours, and resolves within 7-14 days 4, 3. Benzodiazepines should not be used beyond 10-14 days to avoid dependence 4.

Key Safety Considerations

  • Hepatotoxicity risk: Naltrexone can cause hepatocellular injury, particularly at doses >50 mg 5, 6. Check baseline liver function tests
  • Precipitated withdrawal: This is the most serious risk. Patients may experience severe manifestations including dysphoria, severe pain, cardiovascular instability 7, 1
  • Post-detox vulnerability: Even after successful detoxification, patients have decreased opioid tolerance and are at high risk of overdose if they relapse 8

Be prepared to manage withdrawal symptomatically with non-opioid medications including clonidine (α2-agonist), antiemetics, benzodiazepines for anxiety, and antidiarrheals 9, 1.

Related Questions

How should I manage a patient with stable vital signs who is on a Clinical Institute Withdrawal Assessment for Alcohol (CIWA‑B) detoxification protocol?
What CIWA‑Ar (Clinical Institute Withdrawal Assessment for Alcohol) monitoring protocol should be used for a patient who drinks 24 oz of beer four times daily?
What is the Clinical Institute Withdrawal Assessment for Alcohol (CIWA‑Ar) scoring system, its interpretation, and recommended treatment thresholds?
In a patient who drinks 2–4 standard drinks per day, should a Clinical Institute Withdrawal Assessment (CIWA‑Ar) protocol be initiated upon admission?
How is alcohol withdrawal diagnosed, including the clinical criteria, CIWA-Ar scoring, and necessary assessments?
What is the recommended treatment for a non‑occlusive thrombus in the right profunda femoris artery?
What is the likely diagnosis for a patient with a solid, non‑fluctuant mass on the inner cheek and ipsilateral headache?
In a 50-year-old woman with abdominal bloating and pain whose prior transabdominal and transvaginal ultrasound did not visualize the ovaries, what is the appropriate next diagnostic step?
Can you provide a comprehensive overview of Parkinson disease, including its epidemiology, etiology, pathophysiology, clinical signs and symptoms, physical examination findings, diagnostic criteria, treatment options, and prognosis?
Should I prescribe the EzPAP (positive expiratory pressure) device for all patients in my chronic tracheostomy and ventilator unit, given that most have hypoxic brain injury or stroke and only a few have neuromuscular respiratory failure or COPD, and can I bill Medicare for its use as a wellness program?
What is the appropriate dosing regimen of colchicine for an acute gout flare in an adult with normal renal and hepatic function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.